A New Paradigm for Treatment of Inflammatory Diseases

Novel, oral small molecule therapies based on
endogenous bioactive lipids.

Thetis’ lead candidate, TP-317, is a potential first-in-class, safe, oral therapy targeted at inflammatory bowel disease (IBD). TP-317 is a new molecular entity that delivers Resolvin E1 (RvE1), a naturally-occurring lipid mediator that resolves inflammation and promotes mucosal healing. In preclinical colitis studies, both TP-317 and RvE1 have been shown to improve clinical, histopathological, and immunological markers of disease activity. However, RvE1 itself has major shortcomings including very poor stability and lack of IP. Enabled by our HEALER technology, TP-317 overcomes these deficits, with prospects for long-term patent exclusivity. Thetis was recently awarded a $2.3 million Fast Track NIH grant supporting TP-317 development.

In addition, Thetis has two Omega-3 based oral agents in development. TP-352 is a novel derivative of docosahexaenoic acid (DHA), which has been shown in NASH patients to reduce liver steatosis, aminotransferase levels, histological inflammation, and other disease markers. This clinical POC data and the expected safety profile of TP-352 together provide the foundation for advancement as a potential first-line therapy in NASH.

TP-252 is a novel derivative of eicosapentaenoic acid (EPA), which has been shown in separate clinical trials to reduce the relapse rate in ulcerative colitis patients and reduce the risk of cardiovascular events in patients with mixed dyslipidemia. TP-252 is funded by a $1.9 million Fast Track NIH grant.